Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.72 +1.13%

+$0.32 today

Market cap
$144.76M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.24M

Average 0.28M

Returns on capital

Sutro Biopharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

144.3%

avg -61.1%

ROIC

-98.5%

avg -43.9%

ROA

-109.9%

avg -35.7%

Analysis

ROE is currently the strongest return metric at 144.3% versus its period average of -61.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jane Chung

Chief Executive Officer & DirectorUSD 1.16M550<0.01%

Hans-Peter Gerber

Chief Scientific OfficerUSD 771.35K623.75K0.04%

Gregory K. Chow

Chief Financial OfficerUSD 520.58K534.72K0.05%

David Pauling

Chief Administrative Officer & General Counsel—520<0.01%

Jonathan Fawcett DPHIL MBBS

VP & Head of Clinical Development————

Lucas Donigian

Senior Vice President of Business Development————

Regina Cheng

Vice President & Controller————

James R. Swartz

Founder————

Kari E. Leetch

Senior VP and Head of People & Culture————

Devendra Luhar

Senior Vice President of Technical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/A+14.8%
-5.6% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +14.8% over three years. Forward estimates point to Revenue at -5.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Sutro Biopharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about STRO's management, answered from reported figures.

Who manages STRO?

Sutro Biopharma, Inc. (STRO) lists 10 active executives. The top listed executive is Hans-Peter Gerber, Chief Scientific Officer.

Are STRO insiders buying or selling?

Recent insider activity shows net buying of $9.08M.